Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksAMYT.L Share News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amryt Pharma Confident In 2018 With Strong First-Half Revenue Growth

Thu, 19th Jul 2018 12:47

LONDON (Alliance News) - Amryt Pharma PLC said on Thursday it expects its performance for 2018 to be in line with current market expectations, following strong trading in the first half.

The orphan diseases-focused pharmaceutical company said that for the first six months of 2018 it made progress on all three of its growth pillars.

These are continued revenue growth and expansion of its lead asset Lojuxta, developments of its late stage pipeline, and product acquisition to leverage its infrastructure in rare diseases.

Revenue for the six months to the end of June was EUR7.0 million, up 14% from EUR6.2 million the year before.

Full-year growth expectations are underpinned by a recent reimbursement decision by NHS England for Lojuxta in patients with homozygous familial hypercholesterolaemia and the success of Amryt's strategy to appoint local distribution partners for new territories.

In addition, the phase three clinical trial with AP101 for epidermolysis bullosa has seen progress, with a pre-planned interim efficacy analysis which is expected to be completed in the fourth quarter of 2018, and top-line data expected in the second quarter of 2019.

"We are pleased with the progress that we have made in the first half of 2018 across all aspects of our business and growth strategy. Our focus on adoption of and access to Lojuxta in new and existing territories is already delivering significant returns and we are confident that this positive momentum will continue in 2018 and beyond," said Chief Executive Officer Joe Wiley.

Shares In Amryt Pharma were up 1.9% at 17.85 pence on Thursday.

More News
8 May 2018 13:13

Former Amryt Pharma Non-Executive Friel Sells 8.4 Million Shares (ALLISS)

LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said on Tuesday a company owned by a former non-executive director has sold 8.4 million shares in the company.Raglan Road Capital Ltd is

Read more
15 Mar 2018 14:15

Amryt 2017 Revenue Soars On Lojuxta Sales As New In-Licence Sealed

LONDON (Alliance News) - Amryt Pharma PLC said Thursday it has signed an in-licence agreement for a gene therapy platform, with the company making a "very start in for to

Read more
15 Mar 2018 05:25

UK Stocks-Factors to watch on March 15

March 15 (Reuters) - Britain's FTSE 100 index is seen opening 2 points higher at 7,135 on Thursday, according to financial bookmakers. * SHELL: Royal Dutch Shell is close to

Read more
8 Mar 2018 15:39

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 9 March SIGFull Year ResultsInmarsatFull Year ResultsGVC Year 12

Read more
6 Feb 2017 09:23

Amryt Pharma Gets Positive Study Results For Possible Acromegaly Drug

Read more
2 Dec 2016 08:07

Amryt Pharma secures €20m loan from European Investment Bank

(ShareCast News) - AIM-listed Amryt Pharma has secured a €20m loan from the European Investment Bank to secure its near and mid-term funding for its gel product and a development for a drug compound compound. The loan secures funding for its product Episalvan, which treats skin disorder Epidermolysi

Read more
7 Nov 2016 12:19

Amryt Pharma's drug compound gains FDA approval

(ShareCast News) - The US Food and Drug Administration (FDA) has granted orphan drug designation to AIM-listed Amryt Pharma's drug compound which has the potential to treat acromegaly. The drug compound, AP102, now qualifies for tax credits for qualified clinical trials and market exclusivity on reg

Read more
13 Sep 2016 16:10

Amryt Pharma positive about drug developments

(ShareCast News) - Clinical stage specialty pharma company focused on best in class treatments for orphan diseases, Amryt Pharma, posted its interim financial statements for the six months to 30 June on Tuesday. The AIM-traded firm was admitted to trading on AIM and the ESM market of the Irish Stock

Read more
9 Jun 2016 09:55

Amryt Pharma Plans Trials Of Episalvan Product By End Of 2016

Read more
19 Apr 2016 12:05

Amryt Pharma reverses onto AIM to advance orphan drug strategy

(ShareCast News) - Speciality drug developer Amryt Pharma has completed its flotation via the reverse takeover of AIM-listed Fastnet, raising £10m of new cash in the process and acquiring two operating companies. As part of the float, Amryt acquired drug German drug development and manufacturing com

Read more
19 Apr 2016 08:52

Amryt Pharma Starts Trading After Fastnet Reverse Takeover (ALLIPO)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.